AstraZeneca Annual Report and Form 20-F Information 2011

The Manchester Collaborative Centre forInflammation Research is being created by theUniversity of Manchester, GSK and AstraZenecato establish a world-leading centre for inflammatorydiseases. It is a unique collaboration that beganwith an initial investment of £5 million from eachpartner over a three-year period and will bringtogether scientists from both the pharmaceuticalindustry and academia.> A groundbreaking agreement with the UK MedicalResearch Council (MRC) means a wide range ofchemical compounds developed by AstraZenecais to be made available free of charge to UKmedical researchers. As part of the collaborationwith AstraZeneca, the MRC is inviting researchproposals from across the UK academiccommunity to use the compounds in new areas.The MRC will judge and select the best scientificproposals, and award up to £10 million in total tofund research across a broad range of humandiseases. Sir John Savill, Chief Executive of theMRC said: “The initiative marks a new era inmedical discovery, open innovation and publicprivatecollaboration.”Our contribution tobetter health is foundedon the R&D of innovativemedicines that make areal difference in thetreatment of disease.For more information:> See from page 30 in the Business Review> In the US, we used social media channels to supportthe recruitment of patients into Phase III clinical trialsfor NKTR-118 which seek to determine whether themedicine is safe and effective for patients sufferingfrom opioid-induced constipation.1stThe positive decision in Germany in favour ofBrilique, our treatment for acute coronarysyndromes, was the first to be made under the newlaw for the mandatory pricing assessment for newlyintroduced drugs in their healthcare system.14 Health InnovationAstraZeneca Annual Report and Form 20-F Information 2011